Table 5. Response after PBSCT . No. .... | American Society of Hematology

Table 5.

Response after PBSCT

	No.	Response, %	Stable, %	Not evaluated, %
Neurologic	16	87	0	13
Subjective	16	87	0	13
Nerve conduction studies at 1 y	11	36	9	55
Neuropathy impairment score	16^*	25	12	56
Hematologic	16	56	6	37
Nonsecretory	3	NA	NA	100
Immunofixation only	7	43	14	43
SPEP evaluable	6	100†	0	0
Organ	11	82	0	18
Hepatomegaly	5	60	0	40
Splenomegaly	10	50	20	30
Lymphadenopathy	7	71	29	0
Extravascular volume overload	14	79	0	21
Ascites	6	83	0	17
Effusion	4	100	0	0
Edema	14	79	0	21
Dermatologic	13	54	15	31
Papilledema	4	50	0	50
Endocrine	13	23	8	69
Pulmonary	15	20	0	80

	No.	Response, %	Stable, %	Not evaluated, %
Neurologic	16	87	0	13
Subjective	16	87	0	13
Nerve conduction studies at 1 y	11	36	9	55
Neuropathy impairment score	16^*	25	12	56
Hematologic	16	56	6	37
Nonsecretory	3	NA	NA	100
Immunofixation only	7	43	14	43
SPEP evaluable	6	100†	0	0
Organ	11	82	0	18
Hepatomegaly	5	60	0	40
Splenomegaly	10	50	20	30
Lymphadenopathy	7	71	29	0
Extravascular volume overload	14	79	0	21
Ascites	6	83	0	17
Effusion	4	100	0	0
Edema	14	79	0	21
Dermatologic	13	54	15	31
Papilledema	4	50	0	50
Endocrine	13	23	8	69
Pulmonary	15	20	0	80

Median follow-up was 10.8 months. One patient died before evaluation and another patient has not yet returned for evaluation. SPEP indicates serum protein electrophoresis.

One patient showed borderline worsening at 15 months. At 24 months, the patient reported substantial improvement; no repeat neuropathy impairment score was performed.

†

Two complete responses, 3 very good partial responses, and 1 minimal response.

View Large

This Feature Is Available To Subscribers Only